119 related articles for article (PubMed ID: 35046254)
21. [A Case of Pyloric Stenosis Due to Gastric Metastasis of Breast Cancer].
Satoh E; Yatabe Y; Uehira D; Yonekura K; Murakata A; Toyofuku Y; Tanami H; Osanai T; Sugano N; Sakoma T; Maruyama S
Gan To Kagaku Ryoho; 2021 Dec; 48(13):2103-2105. PubMed ID: 35045506
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of BRCA1 and BRCA2 mutation testing to target PARP inhibitor use in platinum-sensitive recurrent ovarian cancer.
Secord AA; Barnett JC; Ledermann JA; Peterson BL; Myers ER; Havrilesky LJ
Int J Gynecol Cancer; 2013 Jun; 23(5):846-52. PubMed ID: 23666017
[TBL] [Abstract][Full Text] [Related]
23. [A Case of Multiple Lung Metastases from Breast Cancer Successfully Treated with Endocrine Therapy].
Goto W; Kashiwagi S; Takada K; Asano Y; Morisaki T; Noda S; Takashima T; Onoda N; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2018 Dec; 45(13):2426-2428. PubMed ID: 30692486
[TBL] [Abstract][Full Text] [Related]
24. A phase I followed by a randomized phase II trial of two cycles carboplatin-olaparib followed by olaparib monotherapy versus capecitabine in BRCA1- or BRCA2-mutated HER2-negative advanced breast cancer as first line treatment (REVIVAL): study protocol for a randomized controlled trial.
Schouten PC; Dackus GM; Marchetti S; van Tinteren H; Sonke GS; Schellens JH; Linn SC
Trials; 2016 Jun; 17(1):293. PubMed ID: 27323902
[TBL] [Abstract][Full Text] [Related]
25. [Occult Breast Carcinoma and Recurrent Tumor in the Breast 14 Years after Axillary Dissection-A Case Report].
Fujimori T; Kasagawa T; Ishii N; Kusashio K; Ozaki D
Gan To Kagaku Ryoho; 2019 Dec; 46(13):2249-2251. PubMed ID: 32156894
[TBL] [Abstract][Full Text] [Related]
26. [A Case of Stage Ⅳ Breast Cancer Treated with Mastectomy after Spontaneous Removal of a Cosmetic Breast Implant].
Mori R; Yanai A; Yanagawa T; Egawa C; Takatsuka Y; Takeno A; Masuzawa T; Hata T; Kagawa Y; Ohmura Y; Katsura Y; Murakami K; Sakamoto T; Takeda Y; Murata K
Gan To Kagaku Ryoho; 2020 Mar; 47(3):542-544. PubMed ID: 32381943
[TBL] [Abstract][Full Text] [Related]
27. Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT-Ov21): a final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial.
Poveda A; Floquet A; Ledermann JA; Asher R; Penson RT; Oza AM; Korach J; Huzarski T; Pignata S; Friedlander M; Baldoni A; Park-Simon TW; Tamura K; Sonke GS; Lisyanskaya A; Kim JH; Filho EA; Milenkova T; Lowe ES; Rowe P; Vergote I; Pujade-Lauraine E;
Lancet Oncol; 2021 May; 22(5):620-631. PubMed ID: 33743851
[TBL] [Abstract][Full Text] [Related]
28. Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.
Ledermann JA; Harter P; Gourley C; Friedlander M; Vergote I; Rustin G; Scott C; Meier W; Shapira-Frommer R; Safra T; Matei D; Fielding A; Spencer S; Rowe P; Lowe E; Hodgson D; Sovak MA; Matulonis U
Lancet Oncol; 2016 Nov; 17(11):1579-1589. PubMed ID: 27617661
[TBL] [Abstract][Full Text] [Related]
29. Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study.
Gelmon KA; Tischkowitz M; Mackay H; Swenerton K; Robidoux A; Tonkin K; Hirte H; Huntsman D; Clemons M; Gilks B; Yerushalmi R; Macpherson E; Carmichael J; Oza A
Lancet Oncol; 2011 Sep; 12(9):852-61. PubMed ID: 21862407
[TBL] [Abstract][Full Text] [Related]
30. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial.
Audeh MW; Carmichael J; Penson RT; Friedlander M; Powell B; Bell-McGuinn KM; Scott C; Weitzel JN; Oaknin A; Loman N; Lu K; Schmutzler RK; Matulonis U; Wickens M; Tutt A
Lancet; 2010 Jul; 376(9737):245-51. PubMed ID: 20609468
[TBL] [Abstract][Full Text] [Related]
31. Salvage treatment for local recurrence following breast-conserving surgery and definitive irradiation for ductal carcinoma in situ (intraductal carcinoma) of the breast.
Solin LJ; Fourquet A; McCormick B; Haffty B; Recht A; Schultz DJ; Barrett W; Fowble BL; Kuske R; Taylor M
Int J Radiat Oncol Biol Phys; 1994 Aug; 30(1):3-9. PubMed ID: 8083125
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of
Saito S; Nakazawa K; Nagahashi M; Ishikawa T; Akazawa K
Per Med; 2019 Nov; 16(6):439-448. PubMed ID: 31692405
[No Abstract] [Full Text] [Related]
33. Extracapsular axillary node extension in patients receiving adjuvant systemic therapy: an indication for radiotherapy?
Fisher BJ; Perera FE; Cooke AL; Opeitum A; Dar AR; Venkatesan VM; Stitt L; Radwan JS
Int J Radiat Oncol Biol Phys; 1997 Jun; 38(3):551-9. PubMed ID: 9231679
[TBL] [Abstract][Full Text] [Related]
34. Chemotherapy port related lymphedema after axillary lymph node dissection.
Turfe Z; Pettinga J; Leduc O; Leduc A; Komorowska-Timek E
Breast; 2016 Aug; 28():145-7. PubMed ID: 27318169
[TBL] [Abstract][Full Text] [Related]
35. Health-related quality of life and patient-centred outcomes with olaparib maintenance after chemotherapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOT Ov-21): a placebo-controlled, phase 3 randomised trial.
Friedlander M; Gebski V; Gibbs E; Davies L; Bloomfield R; Hilpert F; Wenzel LB; Eek D; Rodrigues M; Clamp A; Penson RT; Provencher D; Korach J; Huzarski T; Vidal L; Salutari V; Scott C; Nicoletto MO; Tamura K; Espinoza D; Joly F; Pujade-Lauraine E
Lancet Oncol; 2018 Aug; 19(8):1126-1134. PubMed ID: 30026002
[TBL] [Abstract][Full Text] [Related]
36. [A Case of Recurrent Breast Cancer Treated with Local Irradiation Using Leadless Pacemaker Implantation].
Ishihara S; Kashiwagi S; Asano Y; Tauchi Y; Morisaki T; Noda S; Takashima T; Onoda N; Hirakawa K; Ohira M
Gan To Kagaku Ryoho; 2019 Dec; 46(13):1984-1986. PubMed ID: 32157034
[TBL] [Abstract][Full Text] [Related]
37. A Phase 1 trial of the poly(ADP-ribose) polymerase inhibitor olaparib (AZD2281) in combination with the anti-angiogenic cediranib (AZD2171) in recurrent epithelial ovarian or triple-negative breast cancer.
Liu JF; Tolaney SM; Birrer M; Fleming GF; Buss MK; Dahlberg SE; Lee H; Whalen C; Tyburski K; Winer E; Ivy P; Matulonis UA
Eur J Cancer; 2013 Sep; 49(14):2972-8. PubMed ID: 23810467
[TBL] [Abstract][Full Text] [Related]
38. Hormone signaling via androgen receptor affects breast cancer and prostate cancer in a male patient: A case report.
Takuwa H; Tsuji W; Shintaku M; Yotsumoto F
BMC Cancer; 2018 Dec; 18(1):1282. PubMed ID: 30577860
[TBL] [Abstract][Full Text] [Related]
39. [Importance of Local Therapy for Oligometastatic Breast Cancer-A Case Report].
Kawamata A; Hikino H; Makino Y; Murata Y
Gan To Kagaku Ryoho; 2020 Dec; 47(13):2397-2399. PubMed ID: 33468973
[TBL] [Abstract][Full Text] [Related]
40. [A Case of Ipsilateral Breast Tumor Recurrence with Breast Ulcer].
Oda G; Nakagawa T; Fukuda M; Ishiba T; Kubota K; Fujioka T; Onishi I; Uetake H
Gan To Kagaku Ryoho; 2017 Nov; 44(12):1850-1852. PubMed ID: 29394797
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
